OXIGENE GRANTED U.S. PATENT
Lund and New York - April 15, 1996
OXiGENE, Inc. (NASDAQ:OXGN) today announced that the Company will be granted (notice of allowance) a
U.S. patent covering its product Neu-Sensamide(TM). The patent includes both proprietary formulation and
route of administration claims.
Dr. Bjorn Nordenvall, CEO of OXiGENE comments: "-This is a breakthrough for the Company as we have
hereby obtained a strong and complete patent protection for New- Sensamide(TM). Of particular importance is
that the patent has been allowed without restrictions in accordance with our application. This information means
that we will accelerate our clinical trial program with Neu-Sensamide(TM) and will initiate a phase III trial in lung
cancer and a phase I/II trial in brain cancer during 1996".
Neu-Sensamide(TM) is already protected by OXiGENE's patent (U.S. patent No. 5,340,565) regarding the use
of so called sensitizers to enhance the effect of radiation and chemotherapy in the treatment of cancer. Neu-
Sensamide(TM), a second generation radiosensitizer, is believed by the Company to be of great commercial
potential, as the product can be given intramuscularly and it also has significantly reduced side effects in
comparison to Sensamide(TM), as shown in a recent phase I trial.
OXiGENE, Inc. is focusing on the development of drugs within the Company's core technology area, the cellular
DNA repair mechanism and in particular the enhancement of clinical efficacy of radiation and chemotherapy in
cancer treatment. The Company is currently conducting a clinical phase II/III trial with Sensamide(TM) its first
generation product as a drug for enhancing the effect of radiation treatment in lung cancer. Today 145 patients
out of 226 have been included in the trial which is being conducted in Sweden, Norway, Denmark, Great Britain
and Germany. The OXiGENE share is traded on NASDAQ in the U.S. since 1993. D. Carnegie AB is
conducting an unofficial trad